Wang Jih-Pyang, Hsu Mei-Feng, Ko Horng-Huey, Lin Chun-Nan
Department of Education and Research, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China.
Naunyn Schmiedebergs Arch Pharmacol. 2004 Dec;370(6):500-9. doi: 10.1007/s00210-004-0997-3. Epub 2004 Nov 19.
Kazinol B, a natural isoprenylated flavan, stimulated the Ca(2+) elevation in the presence or absence of Ca(2+) in the medium. Treatment with chymotrypsin or phorbol 12-myristate 13-acetate to shedding of L: -selectin had no effect on subsequent kazinol B-induced Ca(2+) response. Upon initial cyclopiazonic acid (CPA) treatment in the absence of external Ca(2+), the subsequent Ca(2+) rise followed by challenge with kazinol B was greatly diminished. The ryanodine receptor blockers, 8-bromo-cyclic ADP-ribose and ruthenium red did not affect kazinol B-evoked Ca(2+) release from internal stores. However, the inhibitors of sphingosine kinase, dimethylsphingosine, but not dihydrosphingosine, inhibited kazinol B-induced Ca(2+) release. Kazinol B-induced Ca(2+) rise was not affected by two nitric oxidase inhibitors, N-(3-aminomethyl)benzylacetamidine (1400W) and 7-nitroindazole, cytochalasin B and Na(+)-deprivation. This response was slightly attenuated by 2-aminoethyldiphenyl borate (2-APB), a D: -myo-inositol 1,4,5-trisphosphate (IP(3)) receptor blocker, and by genistein, a general tyrosine kinase inhibitor. However, the Ca(2+) response was greatly diminished by two actin filament reorganizers, calyculin A and jasplakinolide, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY 294002), an inhibitor of phosphoinositide 3-kinase, N-(3-aminomethyl)benzylacetamidine (SB 203580), the p38 mitogen-activated protein kinase inhibitor, 1-[6-[17beta-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U-73122), the inhibitor of phospholipase C-coupled processes, and by 0.3 mM La(3+) or Ni(2+). Kazinol B did not evoke any appreciable Ba(2+) and Sr(2+) entry into cells. The Ca(2+) entry blockers, 1-[beta-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole (SKF-96365), but not cis-N-(2-phenylcyclopentyl)azacyclotridec-1-en-2-amine (MDL-12,330A), inhibited a kazinol B-induced Ca(2+) rise. Kazinol B had no effect on the pharmacologically isolated plasma membrane Ca(2+)-ATPase activity. In a Ca(2+)-free medium, kazinol B inhibited the subsequent Ca(2+) addition, resulting in robust entry in CPA- and formyl peptide-activated cells. Kazinol B produced a concentration-dependent reduction in the mitochondrial membrane potential. These results indicate that kazinol B stimulates Ca(2+) release from internal Ca(2+) store, probably through the sphingosine 1-phosphate and IP(3) signaling, and activates external Ca(2+) influx mainly through a non-store-operated Ca(2+) entry (non-SOCE) pathway. Inhibition of SOCE by kazinol B is probably attributable to a break in the Ca(2+) driven force of mitochondria.
卡齐诺醇B是一种天然的异戊烯基化黄酮,无论培养基中是否存在Ca(2+),它都能刺激细胞内Ca(2+)浓度升高。用胰凝乳蛋白酶或佛波酯12 -肉豆蔻酸酯13 -乙酸酯处理以促使L -选择素脱落,对随后卡齐诺醇B诱导的Ca(2+)反应没有影响。在无细胞外Ca(2+)的情况下先用环匹阿尼酸(CPA)处理,随后用卡齐诺醇B刺激时,细胞内Ca(2+)的升高幅度会大大降低。兰尼碱受体阻滞剂8 -溴环二磷酸腺苷核糖和钌红不影响卡齐诺醇B从细胞内储存库诱发的Ca(2+)释放。然而,鞘氨醇激酶抑制剂二甲基鞘氨醇(而非二氢鞘氨醇)可抑制卡齐诺醇B诱导的Ca(2+)释放。卡齐诺醇B诱导的细胞内Ca(2+)升高不受两种一氧化氮合酶抑制剂N -(3 -氨甲基)苄基乙脒(1400W)和7 -硝基吲唑、细胞松弛素B以及钠缺失的影响。这种反应会被D -肌醇1,4,5 -三磷酸(IP(3))受体阻滞剂2 -氨基乙基二苯基硼酸盐(2 - APB)和一般酪氨酸激酶抑制剂染料木黄酮轻微减弱。然而,两种肌动蛋白丝重组剂、花萼海绵诱癌素A和茉莉酮酸甲酯、磷酸肌醇3 -激酶抑制剂2 -(4 -吗啉基)- 8 -苯基- 4H - 1 -苯并吡喃- 4 -酮(LY 294002)、p38丝裂原活化蛋白激酶抑制剂N -(3 -氨甲基)苄基乙脒(SB 203580)、磷脂酶C偶联过程抑制剂1 - [6 - [17β - 3 -甲氧基雌甾- 1,3,5(10) -三烯- 17 -基]氨基]己基]- 1H -吡咯- 2,5 -二酮(U - 73122)以及0.3 mM的La(3+)或Ni(2+)会使Ca(2+)反应大大减弱。卡齐诺醇B不会引起任何明显的Ba(2+)和Sr(2+)进入细胞。Ca(2+)进入阻滞剂1 - [β - [3 -(4 -甲氧基苯基)丙氧基]- 4 -甲氧基苯乙基]- 1H -咪唑(SKF - 96365)(而非顺式 - N -(2 -苯基环戊基)氮杂环十三碳 - 1 -烯 - 2 -胺(MDL - 12,330A))可抑制卡齐诺醇B诱导的细胞内Ca(2+)升高。卡齐诺醇B对药理学分离的质膜Ca(2+) - ATP酶活性没有影响。在无Ca(2+)的培养基中,卡齐诺醇B会抑制随后添加的Ca(2+),导致CPA和甲酰肽激活的细胞中Ca(2+)大量进入。卡齐诺醇B使线粒体膜电位呈浓度依赖性降低。这些结果表明,卡齐诺醇B可能通过鞘氨醇1 -磷酸和IP(3)信号传导刺激细胞内Ca(2+)储存库释放Ca(2+),并主要通过非储存性Ca(2+)内流(非SOCE)途径激活细胞外Ca(2+)内流。卡齐诺醇B对SOCE的抑制可能归因于线粒体Ca(2+)驱动力的中断。